Dyne Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
13/08/2024 02:53
* Dyne Therapeutics Inc DYN.OQ reported a quarterly
adjusted
loss of 70 cents per share for the quarter ended in June,
higher than the same quarter last year, when the company
reported EPS of $-1.08. The mean expectation of ten analysts
for the quarter was for a loss of 72 cents per share. Wall
Street expected results to range from -97 cents to -59 cents per
share.
* Reported revenue was zero; analysts expected zero.
* Dyne Therapeutics Inc's reported EPS for the quarter was a
loss
of 70 cents.
* The company reported a quarterly loss of $65.1 million.
* Dyne Therapeutics Inc shares had risen by 23.5% this
quarter and
gained 227.8% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 2.6%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 10 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is "buy."
Wall Street's median 12-month price target for Dyne Therapeutics
Inc is $45.00
This summary was machine generated from LSEG data August 13 at
01:53 a.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -0.72 -0.70 Beat
Mar. 31 2024 -0.80 -0.81 Missed
Dec. 31 2023 -0.92 -1.09 Missed
Sep. 30 2023 -0.83 -0.99 Missed